HIV Vaccines: Time to do what we need to do
Inline image

By Jennifer Anyanti MPH

Deputy Managing Director, Society for Family Health

It is interesting how the focus is once again shifting from placing all on treatment to continuing the search for the HIV Vaccine. Everywhere it has been proven that vaccines are more cost effective than treatment, in fact as the adage goes, ‘prevention is better than cure’.

The advantages of a vaccine are innumerable, including the fact that they are reducing the need for expensive social and behavioural change messages which, while necessary, tend to be quite expensive.

These are funds that could be shifted into purchasing more vaccines, and allow governments and non-governmental actors to address other areas of programing, including strengthening supply chains which will favour other areas of health.

In addition, the vaccine can target children, and infants that may become infected due to MTCT, which in countries like Nigeria, is still proving to be a tough nut to crack with less than 50% of those who need treatment being on treatment.

Also, in view of the challenges with funding health care in Nigeria and reaching the numbers in the Abuja declaration of 15% for health (http://www.who.int/healthsystems/publications/abuja_declaration/en/), Nigeria was still at less than 5%, except in one state (https://www.dailytrust.com.ng/2018-budget-bauchi-allocates-18-8-to-education-15-23-to-health-sectors.html) and as a result more funds can be used to address the plethora of diseases yet to be addressed in Nigeria.

Despite the advantages inherent in having a vaccine, some key issues need to be addressed. As stated by Gary J. Nabel of the Vaccine Research CenterNIH, in Bethesda, Maryland, a number of areas must be taken into consideration before scientific research will culminate in a definitive AIDS vaccine.

These include the need for greater translation between animal models and human trials and the fact that new, more effective, and more easily produced vectors must be identified.

It is also obvious that the understanding of the immune response to potential vaccine candidates is still yet to be clear.

In addition, in Africa which is still the worse continent affected by the epidemic, insufficient work is being done on research into a vaccine, apart for trials, which are more often than not externally funded.

The need to collaborate strongly with African institutes of research and community advocates cannot be over emphasized.

Also, the issues that also affect vaccination in general such as supply chains, strategic behavioral communication for change and training of health workers will also require consideration and planning.

The hope is that an effective vaccine for HIV could be completed in the next few years (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401528/). Well, millions of those affected or at risk of being affected by HIV are waiting with bated breath.